Literature DB >> 8147892

Activation of src family kinase lck following CD28 crosslinking in the Jurkat leukemic cell line.

A August1, B Dupont.   

Abstract

T lymphocytes require a signal via their antigen specific receptors (the T cell receptors) and an antigen independent costimulatory signal. Signals through CD28 can costimulate T cells in the presence of limiting amounts of T cell receptor signal, or in the presence of PMA, providing this second signal. CD28 signaling is known to involve the activation of protein tyrosine kinases. Using the Jurkat leukemic cell line as a model, we have tested CD28 crosslinking for its effects on the protein tyrosine kinases p56lck. We report that following crosslinking of CD28, p56lck kinase activity is increased. Crosslinking CD28 causes a shift in the relative mobility of p56lck from 56 to 60 kD similar to that seen after crosslinking of CD2 and CD4, cell surface receptors known to be associate with and activate p56lck. Finally, lck could be found in anti-CD28 immunoprecipitates in exponentially growing Jurkat and in "activated" CD28 (i.e., cross linked), but not in CD28 in resting Jurkat cells. These findings suggest an important role for p56lck in CD28 signal transduction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8147892     DOI: 10.1006/bbrc.1994.1396

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  TCR-independent CD28-mediated gene expression in peripheral blood lymphocytes from donors chronically infected with HIV-1.

Authors:  J G Wong; M D Smithgall; O K Haffar
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

2.  Genetic evidence of a role for Lck in T-cell receptor function independent or downstream of ZAP-70/Syk protein tyrosine kinases.

Authors:  J Wong; D Straus; A C Chan
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

3.  Efficient CD28 signalling leads to increases in the kinase activities of the TEC family tyrosine kinase EMT/ITK/TSK and the SRC family tyrosine kinase LCK.

Authors:  S Gibson; K Truitt; Y Lu; R Lapushin; H Khan; J B Imboden; G B Mills
Journal:  Biochem J       Date:  1998-03-15       Impact factor: 3.857

Review 4.  CD28/CTLA-4 and CD80/CD86 families: signaling and function.

Authors:  J M Slavik; J E Hutchcroft; B E Bierer
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 5.  CD28: a signalling perspective.

Authors:  S G Ward
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

6.  Phorbol ester treatment inhibits phosphatidylinositol 3-kinase activation by, and association with, CD28, a T-lymphocyte surface receptor.

Authors:  J E Hutchcroft; D P Franklin; B Tsai; D Harrison-Findik; L Varticovski; B E Bierer
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

7.  p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: implications for T-cell costimulation.

Authors:  M Raab; Y C Cai; S C Bunnell; S D Heyeck; L J Berg; C E Rudd
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

8.  CD28 is associated with and induces the immediate tyrosine phosphorylation and activation of the Tec family kinase ITK/EMT in the human Jurkat leukemic T-cell line.

Authors:  A August; S Gibson; Y Kawakami; T Kawakami; G B Mills; B Dupont
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

9.  Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation.

Authors:  V A Boussiotis; D L Barber; B J Lee; J G Gribben; G J Freeman; L M Nadler
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

10.  Proline residues in CD28 and the Src homology (SH)3 domain of Lck are required for T cell costimulation.

Authors:  A D Holdorf; J M Green; S D Levin; M F Denny; D B Straus; V Link; P S Changelian; P M Allen; A S Shaw
Journal:  J Exp Med       Date:  1999-08-02       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.